Yabao Pharmaceutical (600351.SH): ZY-A002 obtained the Drug Clinical Trial Approval Notice.

Wisdom Finance APP News, Yabao Pharmaceutical (600351.SH) announced recently that the company has received the approval letter of ZY-A002 "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA) (Notice number: 2025LP02459), approving the conduct of confirmatory clinical trials for children with cough-variant asthma.